Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma

References

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma.The Non-Hodgkin's Lymphoma Classification Project.Blood1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H, . A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.
   PubMed Web of Science ®Google Scholar
• Melnyk A, Rodríguez A, Pugh WC, . Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997;89:4514–4520.
   PubMed Web of Science ®Google Scholar
• López-Guillermo A, Cid J, Salar A, . Peripheral T-cell lymphomas: initial features, natural history and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol 1998;9:849–855.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E, . Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d’études des lymphomas de l'adulte (GELA).Blood 1998;92:76–82.
   PubMed Web of Science ®Google Scholar
• Rudiger T, Weisenburger DD, Anderson JR, . Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project. Ann Oncol 2002;13:140–149.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Vose JM, Linder J, . Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. J Clin Oncol 1989;7:1783–1790.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Brousse N, Peuchmaur M, . Peripheral T-cell lymphomas have a worse prognosis than B cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etudes des Lymphomes Aggressives).Ann Oncol 1990;1:45–50.
   PubMed Web of Science ®Google Scholar
• Rodríguez J, Munsell M, Yazji S, . Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001;19:3766–3770.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Nimer S, Zelenetz A, . Similar outcomes for chemosensitive (CS) relapsed or primary refractory peripheral T-cell lymphoma (PTCL) and diffuse large B-cell lymphoma (DLBCL) treated with autologous transplantation (ASCT). Blood 2002;100:646a.
   Web of Science ®Google Scholar
• Caballero MD, Pérez-Simon JA, Iriondo A, . High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003;14:140–151.
   PubMed Web of Science ®Google Scholar
• Blystad AK, Enblad G, Kvaloy S, . High-dose therapy with autologous stem cell transplantation in patients with peripheral T-cell lymphomas. Bone Marrow Transplant 2001;27:711–716.
   PubMed Web of Science ®Google Scholar
• Angelopoulou MK, Nademanee A, Davis A, . Comparison of outcome of high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) in peripheral T cell lymphoma (PTCL) vs. DLBCL (B-DLCL). Blood 2003;102:247a.
   Google Scholar
• Song KW, Mollee P, Keating A, . Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003;120:978–985.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapsed or chemotherapy-sensitive non-Hodgkin lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, . World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
   Google Scholar
• Gascoyne RD, Aoun P, Wu D, . Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93:3913–3921.
   PubMed Web of Science ®Google Scholar
• Falini B, Pileri S, Zinzani PL, . ALK lymphoma: clinico-pathological findings and outcome. Blood 1999;93:2697–2706.
   PubMed Web of Science ®Google Scholar
• Rodríguez J, Cabanillas F, McLaughlin P, . A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the “tumor score”. Ann Oncol 1992;3:711–717.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, . Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474–2479.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   Web of Science ®Google Scholar
• Jostig A, Rueffer U, Franklin J, . Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280–1286.
   PubMed Web of Science ®Google Scholar
• Crump M, Smith AM, Brandwein J, . High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993;11:704–711.
   PubMed Web of Science ®Google Scholar
• Guglielmi C, Gomez F, Philip T, . Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998;16:3264–3269.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Wiklund T, Juvonen E, . Autologous stem cell transplantation in adults patients with peripheral T-cell lymphoma:a nation-wide survey. Bone Marrow Transplant 2004;33:405–410.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Teruya-Feldstein J, . Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006;134:202–207.
   PubMed Web of Science ®Google Scholar
• Smith SD, Bolwell BJ, Rybicki LA, . Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 2007;40:239–243.
   PubMed Web of Science ®Google Scholar
• Feyler S, Prince HM, Pearce R, . The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007;40:443–450.
   PubMed Web of Science ®Google Scholar
• Rodríguez J, Conde E, Gutiérrez A, . The adjusted International Prognostic Index and β-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007;92:1067–1074.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Horwitz SM, Engert A, . Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764–2769.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Hamlin PA, Portlock C, . Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007;139:425–428.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. Curr Opin Hematol 2009;16:299–305.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, . Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190–2196.
   PubMed Web of Science ®Google Scholar
• Gouill S, Milpied N, Buzyn A, . Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults:a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 2008;26:2264–2271.
   PubMed Web of Science ®Google Scholar
• Corradini P, Dodero A, Zallio F, . Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004;22:2172–2176.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Canals C, Finke J, . Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009;27:3951–3958.
   PubMed Web of Science ®Google Scholar